Incyte Corp. (INCY) Net earnings per share growth forecast for next year

Corporate company logo of Incyte Corporation (INCY)

Incyte Corporation (INCY) maintains a high reputation in oncology due to its successful targeted therapies. The stock's performance remains independent of economic cycles, as demand for therapy is stable. Patent protection for Jakafi and strict FDA regulations create powerful barriers to entry for competitors. Changes in earnings per share (EPS) targets reflect current market expectations, where the parameter value equals 157.80.

Incyte Corp. (INCY): Net earnings per share growth forecast for next year from 07/04/2022 to 11/15/2026

Summary analytical data breakdowns for Incyte Corp. (INCY)

- share price and consensus valuation forecast:
Stock Price incyte.com|INCY - Consensus Target
- market capitalization details:
Market Value Incyte|INCY - Total Enterprise Value
- company book value details:
Net Assets per Single Share Incyte|INCY - Company Book Value|Market Value to Book Value Ratio incyte.com|INCY - Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Incyte Corporation|INCY - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio incyte.com|INCY - Company Cumulative Debt|Debt to Book Value Incyte Corp.|INCY - Company Long-Term Loans and Borrowings|Company Current Liabilities Incyte|Quick Ratio incyte.com
- net income and valuation ratios data:
INCY - Final Profit|Projected Future Earnings Incyte Corporation|INCY - Market Cap to Earnings|Future Price to Earnings Incyte|INCY - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Incyte Corporation|INCY - Operating profit EBITDA|Earnings per share for the last twelve months Incyte|INCY - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months incyte.com|INCY - Earnings per share growth rate in current year|Earnings growth forecast for next year Incyte Corporation
- company sales and revenue statistics:
INCY - Company Gross Revenue|Company Projected Revenue Incyte|INCY - Market Cap to Revenue Ratio|Forward P/S Multiple Incyte Corp.
Fundamental company analysis:Incyte Corporation
Finished products of Incyte Corp

Incyte Corporation specializes in developing high-precision targeted therapies with a moderate environmental footprint. The efficiency of new drug development directly determines the consensus estimate for future earnings per share. This indicator measures expected profit dynamics, allowing for a comparison of current forecasts against historical values. Analyzing the modeled EPS growth for the next fiscal year helps identify asset overheating in a timely manner when analyst expectations shift.

Competitor analysis for Incyte Corporation

Net earnings per share growth forecast for next year Hutchison MediPharma|Expected earnings per share growth for next year nuvationbio.com (NUVB)|Net earnings per share growth forecast for next year Day One Biopharmaceuticals Inc (DAWN)|MNPR - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Inhibrx Biosciences Inc INBX|I-Mab - Net earnings per share growth forecast for next year|FENC - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year herontx.com|NVCT: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Coherus CHRS|Expected earnings per share growth for next year CRBP|Expected net earnings per share growth next year Cardiff Oncology CRDF|Expected earnings per share growth for next year BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Expected earnings per share trend next year|Lixte Biotechnology - Expected earnings per share growth for next year|Projected earnings per share increase next year CTXR (Citius Pharma)|Cellectar - Earnings growth forecast for next year|Expected earnings per share trend next year BLRX (BioLineRx Corp)|CANF: Earnings growth forecast for next year|Expected net earnings per share growth next year Aprea (APRE)|Net earnings per share growth forecast for next year kaziatherapeutics.com|SLXN: Expected earnings per share trend next year|Earnings growth forecast for next year NCNA|Earnings growth forecast for next year Chimerix Inc (CMRX)|Net earnings per share growth forecast for next year Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kintara Therapeutics Inc|oncternal.com (ONCT) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)